Business Express is an online portal that covers the latest developments in the world of business and finance. From startups and entrepreneurship to mergers and acquisitions, Business Express provides reporting on the stories that matter most to business leaders and decision-makers.The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.
2024 02 12T055011Z 1 LYNXNPEK1B047 RTROPTP 4 NOVO HOLDINGS INVESTMENT scaled - Business Express

Novo Nordisk’s controlling shareholder plans to invest up to $7 billion a year by 2030 – FT


Novo Nordisk’s controlling shareholder plans to invest up to $7 billion a year by 2030 – FT

(Reuters) – Novo Holdings, the controlling shareholder of Danish obesity drugmaker Novo Nordisk, plans to invest up to $7 billion annually by 2030, the Financial Times reported on Monday.

Kasim Kutay, chief executive of Novo Holdings, told the newspaper that income from its 28% stake in Novo Nordisk and other investments would give the fund $5 billion a year to invest in the next five years.

“We’ve got an ever growing investment portfolio that’s generating very attractive returns,” FT quoted Kutay as saying.

“That’s going to keep on growing, then we’ve got obviously the growth of . . . Ozempic and Wegovy and a lot of dividends . . . we have more money than ever to invest,” he said.

Novo Holdings has 77% of voting shares in Novo Nordisk, the maker of blockbuster obesity drug Wegovy and diabetes treatment Ozempic.

Don't miss out on any breaking news or insightful opinions!
Subscribe to our free newsletter and stay updated on the go!


By submitting this form, you are consenting to receive marketing emails from: . You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact

The move comes soon after Novo Holdings, the investment arm of Novo’s controlling shareholder, the Novo Nordisk Foundation, last week said it would buy Catalent, a key manufacturing subcontractor, for $16.5 billion.

Novo Holdings did not immediately respond to a request for comment asking where it would invest the funds.

 

(Reporting by Mrinmay Dey in Bengaluru; Editing by Janane Venkatraman and Sonia Cheema)

 

Recent Post: